large surface area for modification, are a particularly advantageous vehicle for drug encapsulation and delivery. Nanoparticle-targeted therapies can address multiple mechanisms of IRI. In a range of experimental studies, nanoparticles have been used to target the endothelium and tubular epithelial cells. 7 More recently, nanoparticle targeting to vascular endothelium has been successfully demonstrated in human kidneys during NMP. 8 In this review, we discuss the role of a variety of therapies, ending with nanoparticles, in an isolated, pretransplant setting to prevent complications of IRI.
| S TATE OF RENAL TR AN S PL ANTATI ON
The shortage of suitable donor organs remains one of the leading issues facing renal transplantation today. In an attempt to close this growing gap, the demographics of accepted kidney donations have changed over the past 15 years. Kidneys from extended criteria donors (ECDs) are being considered more frequently. ECDs are estimated to last an average of 5.1 years as compared to standardcriteria donor kidneys, which are projected to function on average for more than 10 years. 9 In addition to ECDs, there has been a significant increase in the use of donation after cardiac death (DCD) kidneys. However, there is some hesitation in using marginal DCD kidneys due to exposure to conditions of warm ischemia prior to procurement. Prolonged warm ischemia has been associated with worsened long-term outcomes in DCD kidney transplants. 10 These kidneys are thought to be markedly more susceptible to the deleterious effects of cold storage and as a result typically have higher rates of delayed graft function (DGF). 11 Due to this concern, around 13% of DCD kidneys retrieved are discarded, even though some of these organs may have yielded successful long-term results. 12 There remains a need for new pretransplant therapies to address the increased susceptibility associated with ECD and DCD kidneys.
Optimizing the use of these marginal organs will require developing comprehensive IRI therapies.
| ISCHEMIA-REPERFUS I ON INJ URY
Clinically, IRI is defined as a sudden period of disrupted blood flow followed by the restoration of an oxygenated blood supply ( Figure 1 ). 1 Histologically, IRI results in tubular necrosis, endothelial and epithelial damage, widespread inflammation, loss of structure, and cyst formation. 13 An ischemic organ will also typically have reduced metabolic function and microvascular damage. IRI is thought to be a factor in the development of acute kidney injury (AKI) and DGF. 14, 15 The severity of IRI can worsen depending on cytokine release at the time of death of the donor and through issues in general management of the organ resulting from the complex logistical nature of transplantation. 16 It is imperative to understand the components behind IRI to develop an appropriate treatment. The period following transplantation, when conditions are being restored to normal, results in a dynamic process of neutrophil activation, increased production of cytokines, expression of adhesion molecules, and release of reactive oxygen species (ROS), resulting in inflammation and cellular necrosis ( Figure 1) . 17, 18 Although the physiology of this process is not entirely understood, reperfusion is known to exacerbate any damage acquired during the period of ischemia. Given that the pathophysiology of IRI is multifactorial, it is likely that effective therapeutic treatments will need to be capable of addressing the various aspects of vascular biology and immune responses involved.
However, both rodent and human studies to date have typically focused on treating singular mechanisms of the injury. As the inflammatory signaling pathways associated with IRI have become clearer, studies have been conducted in rodent models to investigate blocking singular events in these pathways. The Janus kinase/ signal transducer and activator of transcription (JAK/STAT) pathway plays a critical role in cytokine production mediating IRI. 19 Dexmedetomidine, an α2-adrenoreceptor agonist, inhibits the phosphorylation of JAK/STAT proteins, and has proved to be an effective agent in slowing the progression of renal IRI in rodents. 20 Upstream of the JAK/STAT pathway lies nuclear factor kappa B (NF-κB), a transcription factor that has also been shown to regulate the inflammatory cascade in IRI. Rodent studies have demonstrated that the inhibition of NF-κB correlates with the extent of tubular injury, apoptosis, and inflammation within the model. 21 Alternatively, instead of blocking the inflammatory cascade one could administer anticellular adhesion molecules to compete with and inhibit binding between neutrophils and endothelium. 22 Although progress has been made in these model systems, clinical translation remains a challenge.
To date, only a handful of clinical trials have started to investigate methods of ameliorating IRI (NCT00298168, NCT01442337, and NCT00802347). However, these clinical trials did not replicate the same successful outcomes previously demonstrated in rodent models. All the studies in question have faced similar challenges associated with systemic drug delivery and have been discontinued. [23] [24] [25] [26] Traditionally, treatments for IRI (as well as for most other renal diseases) are delivered systemically following transplantation. 27, 28 The primary challenge of the systemic delivery stem is largely driven by the mononuclear phagocyte system (MPS). The MPS consists primarily of monocytes and macrophages present in the liver, spleen, and lymph nodes. This system works to remove foreign bodies, which can include therapeutics, from the circulation, and this often limits the effectiveness of systemically administered drugs. 23 Thus, there remains a significant need for highly specific renal therapies that can overcome the challenges of systemic delivery and adequately alleviate IRI. 3 This has led to the establishment of a UK multicenter randomized control trial (RCT) of NMP versus cold storage in DCD kidneys (ISRCTN15821205). 24 It is possible that NMP can improve some of the deleterious effects of IRI on its own, perhaps by a pre-conditioning mechanism in the setting of a protective, closely monitored environment. In addition to these benefits, NMP serves as a platform to deliver potential treatments to further IRI treatments.
| REPAIR DURING NORMOTHERMIC MACHINE PERFUS ION
NMP presents a unique opportunity to deliver therapies in isolation from the phagocytic system that rapidly eliminates systemi- 
| Perfusate composition
Although major deviations from the original perfusate used by A summary of experimental normothermic perfusion work was compiled following a comprehensive literature review using keyword searches in PubMed. Keywords used to identify relevant studies included normothermic machine perfusion, ex vivo normothermic perfusion, kidney perfusion, and renal perfusion. A methods review was then performed to identify all relevant studies. Experimental NMP work is highlighted in bold. ATP, adenosine triphosphate; CS, cold storage; DBD, donation after brain death; DCD, Donation After Cardiac Death; GFP, green fluorescent protein; GGT, Gamma-Glutamyltransferase; HBD, heart beating donor; HTK, Histidine-tryptophan-ketoglutarate; NGAL, Neutrophil gelatinase-associated lipocalin; UO, urine output; WIT, warm ischemia time.
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initially optimized for normothermic machine perfusion of the lung.
Again, the benefit of this diluent has not been properly assessed in renal NMP. However, it may be impactful for a study to be conducted that systematically examines and optimizes perfusate composition, to maximize all therapeutic results from NMP.
| Gases
As a baseline, 95% oxygen is delivered during NMP and rates of oxygen consumption are used to measure the health of the organ.
Oxygen consumption is maximized at normothermic temperatures, making NMP an ideal system for reconditioning. 25 
| Stem cell therapies
Mesenchymal stromal cells (MSCs) can adapt to their microenvironment and differentiate into several different lineages, all while locally releasing a range of modulatory cytokines. After encouraging results from animal studies, MSC administration has been adapted for preclinical studies, delivered via intravenous infusion after renal transplantation. Although there were no adverse effects noted from these studies, MSCs were shown to be trapped in lung microcapillaries and could not reach the kidneys. 30 At this point no full work has been published on delivering MSCs during any form of NMP; however, it is hypothesized that MSCs will be more effective in this system as they are able to avoid the complications of intravenous delivery.
| Gene therapies
The prospect of altering gene expression in isolated organs ex vivo opens the door for more effective, personalized therapies. In porcine models of ex vivo lung perfusion, adenoviral vector delivery has been demonstrated to be safe and effective. This therapy resulted in a decreased inflammatory response with better graft functionality after transplantation. 31 In the area of renal research, Brasile et al previously demonstrated the ability to target an exogenous gene to the vascular endothelium of a kidney during NMP in a proof-of-concept experiment. 32 To protect the graft from complications of transplantation, gene therapies can be tailored for HLA silencing or to block transcriptional mechanisms of IRI. Introducing other methods of genetic manipulation, for example, siRNA, into the perfusate may require the utilization of stable vehicles for delivery. Nanoparticles have properties that make them ideally suited to this role. In contrast to other theorized treatments, nanoparticles have long-lasting effects and well-established slow-release profiles that extend beyond the period of normothermic perfusion. Recently and for the first time, endothelial targeted nanoparticles have been delivered in an NMP setting. 8 With all of the benefits of this system, NMP is emerging as a device to deliver therapies within an opportunistic window in an attempt to reduce the injurious effects of ischemic injury.
Any drug that is typically delivered systemically can also be introduced during NMP for more concentrated, short-term treatments.
However, when treating IRI, a more prolonged, protective action is desired, as its effects persist long after the initial period of perfusion after transplantation. Each theorized therapy for this system has its own setbacks. What is needed is a modular system that can work across multiple mechanisms of IRI for an extended period.
| NANOPARTI CLE THER APIE S IN NMP
Polymeric nanoparticles (NPs) have a long history of safe use in humans as drug delivery vehicles for the treatment of a wide variety of diseases. [33] [34] [35] One of the primary benefits of NPs is their modularity.
The polymer type can be varied to enable encapsulation of various classes of therapeutics from small molecules to nucleic acid-based drugs. 35, 36 In addition, NPs can be formulated to provide sustained therapeutic release with the rate of release controlled by polymer molecular weight. Finally, the polymer surface can also be modified Following systemic delivery, most varieties of NPs are rapidly eliminated via phagocytes in the liver and spleen (via the aforementioned MPS). 37 This results in a relatively low accumulation of NPs at the desired site of therapeutic delivery and creates the potential for off-target toxicity. 38 To achieve higher accumulation at sites of disease, NPs have more recently been manufactured to have "stealth"
properties in order to evade the immune system and thereby extend circulation times. 39 However, this method is not entirely effective and can still result in relatively short circulation half-lives and high levels of off-target accumulation. Another popular strategy utilized in an attempt to introduce more reliable anatomic specificity is "molecular targeting." This approach employs conjugation of ligands to the NP surface, with the ligand selected on the basis of specificity for a receptor expressed on the target cell type of interest. Although this strategy seems logical, it is important to note that the forces that govern ligand-receptor interactions (eg, hydrogen bonds, electrostatics) only operate over a distance of ~0.3-0.5 nm. 40 Thus targeting is not capable of equipping NPs with a capacity to "home" to sites of interest, 5, 33, 34 but rather can only enhance the likelihood that an NP will be retained by a cell it happens to contact. Consequently, molecular targeting has not been a reliable approach for controlling the anatomic localization of systemically administered NPs.
Although enhanced retention through the conjugation of ligands may not always be effective in systemic delivery, it is in many ways perfectly suited for an isolated NMP setting. 6, 33 In the context of an isolated organ, NPs can largely avoid the challenges associated with systemic delivery. An oxygenated plasma-free red cell solution is used to perfuse the organ, which obviates any complications that may arise from opsonization by serum proteins or tissue-resident phagocytes. Moreover, studies have shown that targeting will typically lead to internalization of NPs, which then provides an intracellular depot effect for effective drug delivery. 41 Preliminary work with targeted, dye-loaded poly(lactic acid)-poly(ethylene) glycol (PLA-PEG) nanoparticles has provided evidence that enhanced retention in specific vascular beds in kidneys is possible during NMP. 8 Performing studies of this nature in discard human kidneys opens new possibilities in the development of therapeutics.
Polymeric NPs provide a venue for the encapsulation of siRNAs and hydrophobic drugs. 35, 36 Meeting this criteria, small molecules like BAY 11-7082, Parthenolide, and BOT-64 have previously been
shown to inhibit NF-κB activity. 42, 43 If one of these drugs was to be encapsulated in polymeric NPs and delivered to kidneys prior to transplantation, it could alleviate the detrimental effects of IRI after transplant. 44 Targeted, drug-loaded NPs if delivered prior to transplant, could block mechanisms leading to inflammatory cascades, thereby limiting damage from IRI ( Figure 2 ). Testing the effects of these drugs during NMP helps us to mitigate any challenges that arise from cell culture or rodent models. Results from Tietjen et al highlighted that while there was an 80-fold benefit of targeting observed in cell culture, this result translated to an average 2-to 4-fold benefit in target specificity when applied to an NMP setting. 8 This phenomenon has been observed in a plethora of studies investigating the efficacy of NPs as therapeutic agents and necessitates more therapeutically relevant models. of NMP can further improve the reconditioning effect. 24, 45, 46 To properly assess the efficacy of a therapeutic treatment, like extended perfusion, more comprehensive diagnostic tools must come to fruition. Although the number of marginal kidney transplants has increased, there has been little progress in the F I G U R E 2 Using NPs as a therapeutic agent in IRI. The use of targeted, drug-loaded NPs can serve as a therapy that blocks more than one mechanism of IRI (eg, neutrophil binding to endothelial cells and NF-κB activity) development of a rigorous quality assessment for marginal kidneys. Currently, NMP also allows us to monitor to the organ and assess its quality. Outcome measures typically include renal blood flow, urine output, mean arterial pressure, oxygen consumption, creatinine clearance, ion concentrations, metabolic markers, and histologic analysis. A variety of biomarkers are assessed to determine the health of the organ, but a specific biomarker for IRI has yet to be identified. Most of these measures are providing clinicians with only superficial, regional information. It is likely that the quality of a perfusion is not uniform throughout the entire organ and that biopsies may only give insight into a certain section of the tissue. To properly gauge how well a kidney has reperfused, and how therapies are affecting the microenvironment, we must be able to look inside of the organ.
| REMAINING CHALLENG E S

| CON CLUS ION
As the number of ECD and DCD kidney transplants rises, IRI is becoming an increasingly prominent issue. Current renal therapies face classic challenges of systemic delivery and there is a scarcity of clinical trials investigating the matter. NMP serves as an ideal platform for isolated treatments. Targeted, drug-loaded NPs delivered during a period of NMP may be the future of IRI therapy in renal transplantation, providing long-lasting, stable therapies.
Before any significant advances can be made with therapeutic treatments, more comprehensive diagnostic tools for this setting must be realized.
